星空传媒91传媒制片厂|明星换脸五级片|麻豆传媒映画女演员王茜|麻豆在传媒在线|九九国产|91制片厂在线观看一二区|夜夜草视频|四虎影院在线播放|国产精品亚洲国际在线看|大象传媒国产第一页,麻豆映画传媒有免费的吗,91制片厂安卓,亚洲成年人精选,91你懂得国产,爱豆视传媒短视频免费,免费一级片

The ZA001 F1F3 ointment, independently developed by Zhong'ao Biopharm, a biopharmaceutical technology in the Bay Area Medicine Valley in Zhongshan's Torch Development Zone, obtained clinical trial approval from the National Medical Products Administration on February 19. It is expected to reshape the global treatment landscape of HPV-related diseases.

The company is also targeting the 6-billion-US dollars market for skin precancerous lesions and is set to initiate clinical trials in Australia.

Akeso, another leading enterprise in the Bay Area Medicine Valley, has also started the new year with a series of successes.

In mid-February, Akeso's Investigational New Drug application for AK139, a bispecific antibody targeting IL-4Rα and ST2, was accepted by the China National Medical Products Administration, following the acceptance of the New Drug Application for the company's self-developed IL-17-targeting monoclonal antibody gumokimab on January 27.

A complete ecosystem, from original innovation to industrial transformation, has been developed within the Bay Area Medicine Valley. It now boasts 94 pharmaceutical pipelines in research, nearly 30 Class-I new drugs under research and 6 Class-I new drugs launched in the market, covering fields such as oncology, immunology and infectious diseases.